文献速递临床试验与 GCP真实世界研究与卫生经济流行病学与生物统计

HepCATT干预在基层医疗中提高丙肝检测与治疗的成本效果:整群随机对照试验

Cost effectiveness of an intervention to increase uptake of hepatitis C virus testing and treatment (HepCATT): cluster randomised controlled trial in primary care.
PubMed 文献 · BMJ · 2020-02-26

该研究在英格兰西南部45家全科诊所开展实用型两臂整群随机对照试验及经济评价,评估电子算法标记、教育培训和患者邀请等综合干预对丙肝病毒(HCV)检测与治疗的影响。干预组标记患者检测率16%,对照组10%,调整率比1.59(95%CI 1.21-2.08;P<0.001);结论认为HepCATT影响温和但成本低,值得优化并纳入NHS策略。

要点

  • HepCATT干预使标记患者HCV检测率从10%提高至16%,调整率比1.59。
  • 干预组HCV抗体阳性率6.2%,对照组4.4%,调整风险比1.40(95%CI 0.99-1.95)。
  • 每额外一例肝病评估成本3165英镑,增量成本效果比每QALY 6212英镑。

核心结论

  • HepCATT干预对提高HCV检测与治疗影响温和但成本低,值得优化并作为NHS策略的一部分实施。

研究设计与样本

  • 实用型两臂实践水平整群随机对照试验及经济评价,纳入英格兰西南部45家全科诊所(干预组22家,对照组23家)。

主要发现

  • 干预组标记患者检测2071例(16%),对照组1163例(10%),调整率比1.59(95%CI 1.21-2.08;P<0.001)。
  • 干预组检出HCV抗体129例,对照组51例,调整率比2.24(95%CI 1.47-3.42)。
  • 抗体阳性率干预组6.2%,对照组4.4%,调整风险比1.40(95%CI 0.99-1.95)。
  • 转诊与评估调整率比5.78(95%CI 1.6-21.6),风险差每1000人1.3例,需帮助人数为每792例标记患者额外一例诊断、转诊和评估(95%CI 558-1883)。

临床怎么用

  • 在基层医疗中采用电子算法标记HCV风险患者并结合教育培训与患者邀请,可适度提高HCV检测与治疗评估。
  • 该干预成本较低,增量成本效果比符合英国NHS常用支付意愿阈值,可考虑优化后实施。

局限性

  • 对照组23家诊所中仅21家收集了结局数据。
  • 抗体阳性率增加证据较弱(调整风险比95%CI包含1)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the effectiveness and cost effectiveness of a complex intervention in primary care that aims to increase uptake of hepatitis C virus (HCV) case finding and treatment. DESIGN: Pragmatic, two armed, practice level, cluster randomised controlled trial and economic evaluation. SETTING AND PARTICIPANTS: 45 general practices in South West England (22 randomised to intervention and 23 to control arm). Outcome data were collected from all intervention practices and 21/23 control practices. Total number of flagged patients was 24 473 (about 5% of practice list). INTERVENTION: Electronic algorithm and flag on practice systems identifying patients with HCV risk markers (such as history of opioid dependence or HCV tests with no evidence of referral to hepatology), staff educational training in HCV, and practice posters/leaflets to increase patients' awareness. Flagged patients were invited by letter for an HCV test (with one follow-up) and had on-screen pop-ups to encourage opportunistic testing. The intervention lasted one year, with practices recruited April to December 2016. MAIN OUTCOME MEASURES: Primary outcome: uptake of HCV testing. SECONDARY OUTCOMES: number of positive HCV tests and yield (proportion HCV positive); HCV treatment assessment at hepatology; cost effectiveness. RESULTS: Baseline HCV testing of flagged patients (six months before study start) was 608/13 097 (4.6%) in intervention practices and 380/11 376 (3.3%) in control practices. During the study 2071 (16%) of flagged patients in the intervention practices and 1163 (10%) in control practices were tested for HCV: overall intervention effect as an adjusted rate ratio of 1.59 (95% confidence interval 1.21 to 2.08; P<0.001). HCV antibodies were detected in 129 patients from intervention practices and 51 patients from control practices (adjusted rate ratio 2.24, 1.47 to 3.42) with weak evidence of an increase in yield (6.2% v 4.4%; adjusted risk ratio 1.40, 0.99 to 1.95). Referral and assessment increased in intervention practices compared with control practices (adjusted rate ratio 5.78, 1.6 to 21.6) with a risk difference of 1.3 per 1000 and a "number needed to help" of one extra HCV diagnosis, referral, and assessment per 792 (95% confidence interval 558 to 1883) patients flagged. The average cost of HCV case finding was £4.03 (95% confidence interval £2.27 to £5.80) per at risk patient and £3165 per additional patient assessed at hepatology. The incremental cost effectiveness ratio was £6212 per quality adjusted life year (QALY), with 92.5% probability of being below £20 000 per QALY. CONCLUSION: HepCATT had a modest impact but is a low cost intervention that merits optimisation and implementation as part of an NHS strategy to increase HCV testing and treatment. TRIAL REGISTRATION: ISRCTN61788850.

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Roberts K, Macleod J, Metcalfe C, et al. Cost effectiveness of an intervention to increase uptake of hepatitis C virus testing and treatment (HepCATT): cluster randomised controlled trial in primary care. BMJ. 2020. PMID: 32102782. doi:10.1136/bmj.m322

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。